Marková M, Haluzík M, Jiskra J, Haluzíková D, Svobodová J, Rosická M
Ustav hematologie a krevní transfuze, Praha.
Cas Lek Cesk. 2001 Dec 6;140(24):767-9.
Leptin is a protein hormone produced predominantly by adipocytes. Its major role in human body is probably to regulate the food intake through the hypothalamic satiety center. One of the peripheral effects of leptin, which was studied mainly in vitro so far, is its stimulating effect on the haematopoietic stem cells. The information concerning the changes of serum leptin levels in various haematological diseases is very limited. The aim of our study was to explore changes of serum leptin levels in patients with sideropenic anaemia at the time of diagnosis and in the various phases of their treatment.
18 patients with untreated sideropenic anaemia (SA) and 20 healthy age, gender and weight-matched control subjects were included into the study. The blood testing in SA patients was performed before anaemia treatment, at the time of maximal increase of reticulocytes and after haemoglobin levels normalisation. Blood count, serum leptin, erythropoietin (EPO) and transpherine receptor (TfR) levels were estimated in all samples. Basal serum leptin levels in SA patients did not differ significantly from those of control subjects (13.9 +/- 14.6 SD vs 10.4 +/- 8.8 SD ng.ml-1). Treatment anaemia of did not significantly affect the serum leptin levels in SA patients (13.9 +/- 14.6 SD vs 12.9 +/- 12.6 SD vs 12.8 +/- 15.1 SD ng-ml-1). Serum EPO and TfR levels in SA patients were higher before the start of treatment and decreased significantly after the anaemia recovery. In both groups serum leptin levels correlated positively with body mass index. No unambiguous statistically significant relationships between serum leptin levels and blood count parameters or serum EPO and TfR levels were found in any of the groups studied.
Neither the changes of red blood cell count during the sideropenic anemia treatment nor the increased erythropoiesis affect significantly serum leptin levels.
瘦素是一种主要由脂肪细胞产生的蛋白质激素。它在人体中的主要作用可能是通过下丘脑饱食中枢调节食物摄入。瘦素的外周作用之一，目前主要在体外进行研究，即对造血干细胞的刺激作用。关于各种血液系统疾病中血清瘦素水平变化的信息非常有限。我们研究的目的是探讨缺铁性贫血患者在诊断时及其治疗各阶段血清瘦素水平的变化。
18例未经治疗的缺铁性贫血（SA）患者和20例年龄、性别和体重匹配的健康对照者纳入研究。对SA患者在贫血治疗前、网织红细胞最大增加时以及血红蛋白水平正常化后进行血液检测。对所有样本进行血细胞计数、血清瘦素、促红细胞生成素（EPO）和转铁蛋白受体（TfR）水平测定。SA患者的基础血清瘦素水平与对照者无显著差异（13.9±14.6 SD对10.4±8.8 SD ng.ml-1）。治疗贫血对SA患者的血清瘦素水平无显著影响（13.9±14.6 SD对12.9±12.6 SD对12.8±15.1 SD ng-ml-1）。SA患者治疗开始前血清EPO和TfR水平较高，贫血恢复后显著下降。两组血清瘦素水平均与体重指数呈正相关。在所研究的任何一组中，均未发现血清瘦素水平与血细胞计数参数或血清EPO和TfR水平之间存在明确的统计学显著关系。
缺铁性贫血治疗期间红细胞计数的变化以及红细胞生成增加均未显著影响血清瘦素水平。
